$NTRA

Generating a unique summary for NTRA…

AI-generated for information only — not investment advice.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Institutions hold 96.70% · insiders 2.73% · 1,240 institutions

Consensus score 1.35 (1 = strong buy, 5 = sell) · mean target 411.39

• Canaccord GenuityBuymain2026-10-19
• JP MorganOverweightmain2026-10-14
• Morgan StanleyOverweightmain2026-10-13
• TD CowenBuymain2026-10-13
• BarclaysOverweightmain2026-10-07
• CitigroupBuymain2026-10-06
• GuggenheimBuymain2026-10-01
• RBC CapitalOutperformmain2026-09-25
• UBSBuymain2026-09-09
• Rothschild & CoBuyinit2026-09-08

Next report: 2026-11-05

• 10-QPeriodic Financial Reports2026-08-07Open
• 8-KCorporate Changes & Voting Matters2026-08-06Open
• 8-KCorporate Changes & Voting Matters2026-07-06Open
• 8-K/ACorporate Changes & Voting Matters2026-06-16Open
• 8-KCorporate Changes & Voting Matters2026-06-05Open
• 10-QPeriodic Financial Reports2026-05-08Open
• 8-KCorporate Changes & Voting Matters2026-05-07Open
• DEF 14AProxy Statements2026-04-23Open
• 8-KCorporate Changes & Voting Matters2026-04-01Open
• S-8Offering Registrations2026-03-02Open

• Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More

  A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most closely watched names.

  Fri, 23 Oct 2026 11:51:51 +0000

• IBD Stock Of The Day, Natera, Hovering Near Buy Point

  Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.

  Thu, 22 Oct 2026 21:40:45 +0000

• Natera (NTRA) Is Expanding Cancer Testing Rapidly. Does Its Valuation Leave Room for Error?

  Testing Volume Is Growing Faster Than the Valuation Can Ignore Natera, Inc. (NASDAQ:NTRA) is turning personalized cancer monitoring into a growing clinical service, but its valuation prices in much more than today’s test volumes. Its Signatera platform detects molecular residual disease through circulating tumor DNA, helping clinicians assess whether cancer remains or returns after treatment. […]

  Tue, 20 Oct 2026 16:33:29 +0000

• Why Natera (NTRA) Stock Is Up Today

  Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 2.4% in the afternoon session after the company announced that incorporating phased and structural variants enables ctDNA detection significantly below 1 part per 10 million, elevating molecular residual disease sensitivity ahead of the 2026 ESMO Annual Congress.

  Mon, 19 Oct 2026 21:52:55 +0000

• ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

  AUSTIN, Texas, October 18, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.

  Sun, 18 Oct 2026 22:10:00 +0000

• Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

  AUSTIN, Texas, October 15, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.

  Thu, 15 Oct 2026 16:46:00 +0000

• Natera Gains 118.1% in a Year: What's Driving the Rally?

  NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.

  Thu, 15 Oct 2026 12:28:00 +0000

• How FDA Breakthrough Status For Natera’s Multi‑Cancer Test (NTRA) Has Changed Its Investment Story

  Natera, Inc. recently received U.S. FDA Breakthrough Device designation for its investigational multi-cancer early detection blood test, which analyzes cell-free DNA and was evaluated across 12 cancer types for sensitivity, specificity, and cancer signal origin performance. This designation, coupled with prior regulatory progress for Signatera internationally, underscores how Natera’s oncology portfolio is increasingly embedded in late-stage clinical and regulatory pathways across multiple...

  Sat, 10 Oct 2026 15:12:56 +0000